US FDA says all doses of Lilly's weight-loss and diabetes drug now available
Adds FDA response in paragraph 4-5
Aug 2 (Reuters) -All doses of Eli Lilly's LLY.N weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortagelist showedon Friday.
However, the regulator has not yet removed the drugs off its shortage list.
Lilly's Mounjaro has been on the U.S. FDA's shortage list since late 2022, while Zepbound was added to the list in April this year.
The FDA continues to actively monitor drug availability and work with the company to ensure a stable supply of safe and effective drugs, the agency stated in an email.
The health regulator added that even when all doses of a drug are listed as available, additional criteria are considered before moving a drug off the shortages list.
These criteria include whether backorder's have been fulfilled and if the supply is meeting demand.
Lilly did not immediately respond to a Reuters request for comment.
On Thursday, CEO David Ricks told Bloomberg he expected the shortage to be resolved soon.
Surging demand for Mounjaro and Zepbound has led Lilly to invest billions of dollars in boosting their production of these drugs. Danish drugmaker Novo Nordisk NOVOb.CO, which makes rival drugs Ozempic and Wegovy, is also working to ramp up supply.
Originally developed for diabetes, GLP-1 therapies have shown to reduce weight by up to 20% in trials. Some analysts estimate that the market for these therapies could hit $150 billion in revenues by the early 2030s.
Several doses of Novo's Ozempic and Wegovy, both chemically known as semaglutide, have been on the U.S. health regulator's shortage list since early 2022.
Currently, all doses of diabetes drug Ozempic are available in the United States, while three doses of Wegovy remain in limited supply.
Reporting by Bhanvi Satija and Sneha S K in Bengaluru; Editing by Shinjini Ganguli and Tasim Zahid
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
